Table 2

Distribution of different bDMARDs in monotherapy and combination therapy with csDMARDs

bDMARDSStudy populationMonotherapy (N=799)Combination (N=3679)
ABA, n (%)189 (4.22)34 (4.26)155 (4.21)
ADA, n (%)1143 (25.52)201 (25.16)942 (25.60)
CTZ, n (%)156 (3.48)30 (3.75)126 (3.42)
ETA, n (%)1787 (39.91)385 (48.19)1402 (38.11)
GOL, n (%)151 (3.37)21 (2.63)130 (3.53)
INF, n (%)861 (19.23)81 (10.14)780 (21.20)
TCZ, n (%)191 (4.27)47 (5.88)144 (3.91)
  • ABA, abatacept; ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic┬ádisease-modifying antirheumatic drug; CTZ, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab; TCZ, tocilizumab.